Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study
The microbiota interacts with the brain through the gut-brain axis, and a distinct dysbiosis may lead to major depressive episodes. Bacteria can pass through the gut barrier and be found in the blood. Using a multiomic approach, we investigated whether a distinct blood microbiome and metabolome was...
Gespeichert in:
| Veröffentlicht in: | Journal of psychiatry & neuroscience 2021-05, Vol.46 (3), p.E358-E368 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E368 |
|---|---|
| container_issue | 3 |
| container_start_page | E358 |
| container_title | Journal of psychiatry & neuroscience |
| container_volume | 46 |
| creator | Ciocan, Dragos Cassard, Anne-Marie Becquemont, Laurent Verstuyft, Céline Voican, Cosmin Sebastian El Asmar, Khalil Colle, Romain David, Denis Trabado, Séverine Feve, Bruno Chanson, Philippe Perlemuter, Gabriel Corruble, Emmanuelle |
| description | The microbiota interacts with the brain through the gut-brain axis, and a distinct dysbiosis may lead to major depressive episodes. Bacteria can pass through the gut barrier and be found in the blood. Using a multiomic approach, we investigated whether a distinct blood microbiome and metabolome was associated with major depressive episodes, and how it was modulated by treatment.
In this case-control multiomic study, we analyzed the blood microbiome composition, inferred bacterial functions and metabolomic profile of 56 patients experiencing a current major depressive episode and 56 matched healthy controls, before and after treatment, using 16S rDNA sequencing and liquid chromatography coupled to tandem mass spectrometry.
The baseline blood microbiome in patients with a major depressive episode was distinct from that of healthy controls (patients with a major depressive episode had a higher proportion of Janthinobacterium and lower levels of Neisseria) and changed after antidepressant treatment. Predicted microbiome functions confirmed by metabolomic profiling showed that patients who were experiencing a major depressive episode had alterations in the cyanoamino acid pathway at baseline. High baseline levels of Firmicutes and low proportions of Bosea and Tetrasphaera were associated with response to antidepressant treatment. Based on inferred baseline metagenomic profiles, bacterial pathways that were significantly associated with treatment response were related to xenobiotics, amino acids, and lipid and carbohydrate metabolism, including tryptophan and drug metabolism. Metabolomic analyses showed that plasma tryptophan levels are independently associated with response to antidepressant treatment.
Our study has some limitations, including a lack of information on blood microbiome origin and the lack of a validation cohort to confirm our results.
Patients with depression have a distinct blood microbiome and metabolomic signature that changes after treatment. Dysbiosis could be a new therapeutic target and prognostic tool for the treatment of patients who are experiencing a major depressive episode. |
| doi_str_mv | 10.1503/jpn.200159 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8327971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666502665</galeid><sourcerecordid>A666502665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c671t-4b510dbba3ec0c0453f72e4c7489f07968716f4802feca74290800aec2b291c63</originalsourceid><addsrcrecordid>eNqVk99v0zAQxyMEYmPwwh-AIiYhhpRiO07i8IBUJmCTKpD48Ww5zqV1ldqZ7VTsX-Cv5qqW0U59QZGS893nvr7Yd0nynJIJLUj-djnYCSOEFvWD5JRyITLGc_4QbSpIhmt2kjwJYUkIYUg9Tk5yToio8_w0-f2hd65NV0Z71xgXVaosLiGqxvUO3Wkwc6vi6CF1XbpSS-fTFgYPIRhn0wY6h6FNkuoieLSi2cXRTKMHFVdg47tUpYN3YQAdzRpSrQJk2tnoXZ-GOLa3T5NHneoDPNt9z5Kfnz7-uLzKZl8_X19OZ5kuKxoz3hSUtE2jctBEE17kXcWA64qLuiNVXYqKlh0XhHWgVcVZTQQhCjRrWE11mZ8l77e6w9isoNVYnFe9HLxZKX8rnTLyMGLNQs7dWoqcVXVFUeBiK7C4l3Y1ncmNj3A86Lqma4bs691m3t2MEKJcmaCh75UFNwbJCiawQE44ouf30KUbvcWjQKrkhShqUf6j5qoHaWznsEa9EZXTsiwLwvCFVHaEmoMF_CFnoTPoPuBfHuH1YG7kPjQ5AuHTAjbKUdWLg4TNdcOvOFdjCPL6-7f_YL8csq_22AWoPi6C68eIHRkOwTdbELs7BA_d3XVRIjezI3F25HZ2EH6x3xd36N9hyf8A46UROg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564585986</pqid></control><display><type>article</type><title>Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ciocan, Dragos ; Cassard, Anne-Marie ; Becquemont, Laurent ; Verstuyft, Céline ; Voican, Cosmin Sebastian ; El Asmar, Khalil ; Colle, Romain ; David, Denis ; Trabado, Séverine ; Feve, Bruno ; Chanson, Philippe ; Perlemuter, Gabriel ; Corruble, Emmanuelle</creator><creatorcontrib>Ciocan, Dragos ; Cassard, Anne-Marie ; Becquemont, Laurent ; Verstuyft, Céline ; Voican, Cosmin Sebastian ; El Asmar, Khalil ; Colle, Romain ; David, Denis ; Trabado, Séverine ; Feve, Bruno ; Chanson, Philippe ; Perlemuter, Gabriel ; Corruble, Emmanuelle</creatorcontrib><description>The microbiota interacts with the brain through the gut-brain axis, and a distinct dysbiosis may lead to major depressive episodes. Bacteria can pass through the gut barrier and be found in the blood. Using a multiomic approach, we investigated whether a distinct blood microbiome and metabolome was associated with major depressive episodes, and how it was modulated by treatment.
In this case-control multiomic study, we analyzed the blood microbiome composition, inferred bacterial functions and metabolomic profile of 56 patients experiencing a current major depressive episode and 56 matched healthy controls, before and after treatment, using 16S rDNA sequencing and liquid chromatography coupled to tandem mass spectrometry.
The baseline blood microbiome in patients with a major depressive episode was distinct from that of healthy controls (patients with a major depressive episode had a higher proportion of Janthinobacterium and lower levels of Neisseria) and changed after antidepressant treatment. Predicted microbiome functions confirmed by metabolomic profiling showed that patients who were experiencing a major depressive episode had alterations in the cyanoamino acid pathway at baseline. High baseline levels of Firmicutes and low proportions of Bosea and Tetrasphaera were associated with response to antidepressant treatment. Based on inferred baseline metagenomic profiles, bacterial pathways that were significantly associated with treatment response were related to xenobiotics, amino acids, and lipid and carbohydrate metabolism, including tryptophan and drug metabolism. Metabolomic analyses showed that plasma tryptophan levels are independently associated with response to antidepressant treatment.
Our study has some limitations, including a lack of information on blood microbiome origin and the lack of a validation cohort to confirm our results.
Patients with depression have a distinct blood microbiome and metabolomic signature that changes after treatment. Dysbiosis could be a new therapeutic target and prognostic tool for the treatment of patients who are experiencing a major depressive episode.</description><identifier>ISSN: 1180-4882</identifier><identifier>EISSN: 1488-2434</identifier><identifier>DOI: 10.1503/jpn.200159</identifier><identifier>PMID: 34008933</identifier><language>eng</language><publisher>Canada: CMA Joule Inc</publisher><subject>Adult ; Antidepressants ; Antidepressive Agents - pharmacology ; Antidepressive Agents - therapeutic use ; Bacteria ; Bacteria - classification ; Bacteria - drug effects ; Blood ; Blood - drug effects ; Blood - microbiology ; Brain-Gut Axis - drug effects ; Carbohydrate metabolism ; Carbohydrate Metabolism - drug effects ; Case-Control Studies ; Depressive Disorder, Major - blood ; Depressive Disorder, Major - complications ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - microbiology ; Dosage and administration ; Drug metabolism ; Drug therapy ; Dysbacteriosis ; Dysbiosis - blood ; Dysbiosis - complications ; Dysbiosis - metabolism ; Dysbiosis - microbiology ; Female ; Gastrointestinal Microbiome - drug effects ; Health care ; Humans ; Life Sciences ; Lipid metabolism ; Lipid Metabolism - drug effects ; Liquid chromatography ; Major depressive disorder ; Male ; Mass spectroscopy ; Mental depression ; Metabolism ; Metabolites ; Metabolome - drug effects ; Metabolomics ; Metagenomics ; Microbiomes ; Microbiota ; Microbiota (Symbiotic organisms) ; Microbiota - drug effects ; Patient outcomes ; Patients ; Permeability ; Physiological aspects ; Psychosis ; Psychotropic drugs ; Research Paper ; rRNA 16S ; Standard deviation ; Therapeutic targets ; Tryptophan ; Xenobiotics</subject><ispartof>Journal of psychiatry & neuroscience, 2021-05, Vol.46 (3), p.E358-E368</ispartof><rights>2021 CMA Joule Inc. or its licensors.</rights><rights>COPYRIGHT 2021 CMA Joule Inc.</rights><rights>2021. This work is published under https://jpn.ca/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2021 CMA Joule Inc. or its licensors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c671t-4b510dbba3ec0c0453f72e4c7489f07968716f4802feca74290800aec2b291c63</citedby><orcidid>0000-0002-1813-5128 ; 0000-0001-6577-9009 ; 0000-0002-0506-6688 ; 0000-0001-5096-5722</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327971/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327971/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34008933$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04020991$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ciocan, Dragos</creatorcontrib><creatorcontrib>Cassard, Anne-Marie</creatorcontrib><creatorcontrib>Becquemont, Laurent</creatorcontrib><creatorcontrib>Verstuyft, Céline</creatorcontrib><creatorcontrib>Voican, Cosmin Sebastian</creatorcontrib><creatorcontrib>El Asmar, Khalil</creatorcontrib><creatorcontrib>Colle, Romain</creatorcontrib><creatorcontrib>David, Denis</creatorcontrib><creatorcontrib>Trabado, Séverine</creatorcontrib><creatorcontrib>Feve, Bruno</creatorcontrib><creatorcontrib>Chanson, Philippe</creatorcontrib><creatorcontrib>Perlemuter, Gabriel</creatorcontrib><creatorcontrib>Corruble, Emmanuelle</creatorcontrib><title>Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study</title><title>Journal of psychiatry & neuroscience</title><addtitle>J Psychiatry Neurosci</addtitle><description>The microbiota interacts with the brain through the gut-brain axis, and a distinct dysbiosis may lead to major depressive episodes. Bacteria can pass through the gut barrier and be found in the blood. Using a multiomic approach, we investigated whether a distinct blood microbiome and metabolome was associated with major depressive episodes, and how it was modulated by treatment.
In this case-control multiomic study, we analyzed the blood microbiome composition, inferred bacterial functions and metabolomic profile of 56 patients experiencing a current major depressive episode and 56 matched healthy controls, before and after treatment, using 16S rDNA sequencing and liquid chromatography coupled to tandem mass spectrometry.
The baseline blood microbiome in patients with a major depressive episode was distinct from that of healthy controls (patients with a major depressive episode had a higher proportion of Janthinobacterium and lower levels of Neisseria) and changed after antidepressant treatment. Predicted microbiome functions confirmed by metabolomic profiling showed that patients who were experiencing a major depressive episode had alterations in the cyanoamino acid pathway at baseline. High baseline levels of Firmicutes and low proportions of Bosea and Tetrasphaera were associated with response to antidepressant treatment. Based on inferred baseline metagenomic profiles, bacterial pathways that were significantly associated with treatment response were related to xenobiotics, amino acids, and lipid and carbohydrate metabolism, including tryptophan and drug metabolism. Metabolomic analyses showed that plasma tryptophan levels are independently associated with response to antidepressant treatment.
Our study has some limitations, including a lack of information on blood microbiome origin and the lack of a validation cohort to confirm our results.
Patients with depression have a distinct blood microbiome and metabolomic signature that changes after treatment. Dysbiosis could be a new therapeutic target and prognostic tool for the treatment of patients who are experiencing a major depressive episode.</description><subject>Adult</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Bacteria</subject><subject>Bacteria - classification</subject><subject>Bacteria - drug effects</subject><subject>Blood</subject><subject>Blood - drug effects</subject><subject>Blood - microbiology</subject><subject>Brain-Gut Axis - drug effects</subject><subject>Carbohydrate metabolism</subject><subject>Carbohydrate Metabolism - drug effects</subject><subject>Case-Control Studies</subject><subject>Depressive Disorder, Major - blood</subject><subject>Depressive Disorder, Major - complications</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - microbiology</subject><subject>Dosage and administration</subject><subject>Drug metabolism</subject><subject>Drug therapy</subject><subject>Dysbacteriosis</subject><subject>Dysbiosis - blood</subject><subject>Dysbiosis - complications</subject><subject>Dysbiosis - metabolism</subject><subject>Dysbiosis - microbiology</subject><subject>Female</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>Health care</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Lipid metabolism</subject><subject>Lipid Metabolism - drug effects</subject><subject>Liquid chromatography</subject><subject>Major depressive disorder</subject><subject>Male</subject><subject>Mass spectroscopy</subject><subject>Mental depression</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metabolome - drug effects</subject><subject>Metabolomics</subject><subject>Metagenomics</subject><subject>Microbiomes</subject><subject>Microbiota</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>Microbiota - drug effects</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Permeability</subject><subject>Physiological aspects</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><subject>Research Paper</subject><subject>rRNA 16S</subject><subject>Standard deviation</subject><subject>Therapeutic targets</subject><subject>Tryptophan</subject><subject>Xenobiotics</subject><issn>1180-4882</issn><issn>1488-2434</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqVk99v0zAQxyMEYmPwwh-AIiYhhpRiO07i8IBUJmCTKpD48Ww5zqV1ldqZ7VTsX-Cv5qqW0U59QZGS893nvr7Yd0nynJIJLUj-djnYCSOEFvWD5JRyITLGc_4QbSpIhmt2kjwJYUkIYUg9Tk5yToio8_w0-f2hd65NV0Z71xgXVaosLiGqxvUO3Wkwc6vi6CF1XbpSS-fTFgYPIRhn0wY6h6FNkuoieLSi2cXRTKMHFVdg47tUpYN3YQAdzRpSrQJk2tnoXZ-GOLa3T5NHneoDPNt9z5Kfnz7-uLzKZl8_X19OZ5kuKxoz3hSUtE2jctBEE17kXcWA64qLuiNVXYqKlh0XhHWgVcVZTQQhCjRrWE11mZ8l77e6w9isoNVYnFe9HLxZKX8rnTLyMGLNQs7dWoqcVXVFUeBiK7C4l3Y1ncmNj3A86Lqma4bs691m3t2MEKJcmaCh75UFNwbJCiawQE44ouf30KUbvcWjQKrkhShqUf6j5qoHaWznsEa9EZXTsiwLwvCFVHaEmoMF_CFnoTPoPuBfHuH1YG7kPjQ5AuHTAjbKUdWLg4TNdcOvOFdjCPL6-7f_YL8csq_22AWoPi6C68eIHRkOwTdbELs7BA_d3XVRIjezI3F25HZ2EH6x3xd36N9hyf8A46UROg</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Ciocan, Dragos</creator><creator>Cassard, Anne-Marie</creator><creator>Becquemont, Laurent</creator><creator>Verstuyft, Céline</creator><creator>Voican, Cosmin Sebastian</creator><creator>El Asmar, Khalil</creator><creator>Colle, Romain</creator><creator>David, Denis</creator><creator>Trabado, Séverine</creator><creator>Feve, Bruno</creator><creator>Chanson, Philippe</creator><creator>Perlemuter, Gabriel</creator><creator>Corruble, Emmanuelle</creator><general>CMA Joule Inc</general><general>CMA Impact, Inc</general><general>Canadian Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1813-5128</orcidid><orcidid>https://orcid.org/0000-0001-6577-9009</orcidid><orcidid>https://orcid.org/0000-0002-0506-6688</orcidid><orcidid>https://orcid.org/0000-0001-5096-5722</orcidid></search><sort><creationdate>20210501</creationdate><title>Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study</title><author>Ciocan, Dragos ; Cassard, Anne-Marie ; Becquemont, Laurent ; Verstuyft, Céline ; Voican, Cosmin Sebastian ; El Asmar, Khalil ; Colle, Romain ; David, Denis ; Trabado, Séverine ; Feve, Bruno ; Chanson, Philippe ; Perlemuter, Gabriel ; Corruble, Emmanuelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c671t-4b510dbba3ec0c0453f72e4c7489f07968716f4802feca74290800aec2b291c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Bacteria</topic><topic>Bacteria - classification</topic><topic>Bacteria - drug effects</topic><topic>Blood</topic><topic>Blood - drug effects</topic><topic>Blood - microbiology</topic><topic>Brain-Gut Axis - drug effects</topic><topic>Carbohydrate metabolism</topic><topic>Carbohydrate Metabolism - drug effects</topic><topic>Case-Control Studies</topic><topic>Depressive Disorder, Major - blood</topic><topic>Depressive Disorder, Major - complications</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - microbiology</topic><topic>Dosage and administration</topic><topic>Drug metabolism</topic><topic>Drug therapy</topic><topic>Dysbacteriosis</topic><topic>Dysbiosis - blood</topic><topic>Dysbiosis - complications</topic><topic>Dysbiosis - metabolism</topic><topic>Dysbiosis - microbiology</topic><topic>Female</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>Health care</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Lipid metabolism</topic><topic>Lipid Metabolism - drug effects</topic><topic>Liquid chromatography</topic><topic>Major depressive disorder</topic><topic>Male</topic><topic>Mass spectroscopy</topic><topic>Mental depression</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metabolome - drug effects</topic><topic>Metabolomics</topic><topic>Metagenomics</topic><topic>Microbiomes</topic><topic>Microbiota</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>Microbiota - drug effects</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Permeability</topic><topic>Physiological aspects</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><topic>Research Paper</topic><topic>rRNA 16S</topic><topic>Standard deviation</topic><topic>Therapeutic targets</topic><topic>Tryptophan</topic><topic>Xenobiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ciocan, Dragos</creatorcontrib><creatorcontrib>Cassard, Anne-Marie</creatorcontrib><creatorcontrib>Becquemont, Laurent</creatorcontrib><creatorcontrib>Verstuyft, Céline</creatorcontrib><creatorcontrib>Voican, Cosmin Sebastian</creatorcontrib><creatorcontrib>El Asmar, Khalil</creatorcontrib><creatorcontrib>Colle, Romain</creatorcontrib><creatorcontrib>David, Denis</creatorcontrib><creatorcontrib>Trabado, Séverine</creatorcontrib><creatorcontrib>Feve, Bruno</creatorcontrib><creatorcontrib>Chanson, Philippe</creatorcontrib><creatorcontrib>Perlemuter, Gabriel</creatorcontrib><creatorcontrib>Corruble, Emmanuelle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of psychiatry & neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ciocan, Dragos</au><au>Cassard, Anne-Marie</au><au>Becquemont, Laurent</au><au>Verstuyft, Céline</au><au>Voican, Cosmin Sebastian</au><au>El Asmar, Khalil</au><au>Colle, Romain</au><au>David, Denis</au><au>Trabado, Séverine</au><au>Feve, Bruno</au><au>Chanson, Philippe</au><au>Perlemuter, Gabriel</au><au>Corruble, Emmanuelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study</atitle><jtitle>Journal of psychiatry & neuroscience</jtitle><addtitle>J Psychiatry Neurosci</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>46</volume><issue>3</issue><spage>E358</spage><epage>E368</epage><pages>E358-E368</pages><issn>1180-4882</issn><eissn>1488-2434</eissn><abstract>The microbiota interacts with the brain through the gut-brain axis, and a distinct dysbiosis may lead to major depressive episodes. Bacteria can pass through the gut barrier and be found in the blood. Using a multiomic approach, we investigated whether a distinct blood microbiome and metabolome was associated with major depressive episodes, and how it was modulated by treatment.
In this case-control multiomic study, we analyzed the blood microbiome composition, inferred bacterial functions and metabolomic profile of 56 patients experiencing a current major depressive episode and 56 matched healthy controls, before and after treatment, using 16S rDNA sequencing and liquid chromatography coupled to tandem mass spectrometry.
The baseline blood microbiome in patients with a major depressive episode was distinct from that of healthy controls (patients with a major depressive episode had a higher proportion of Janthinobacterium and lower levels of Neisseria) and changed after antidepressant treatment. Predicted microbiome functions confirmed by metabolomic profiling showed that patients who were experiencing a major depressive episode had alterations in the cyanoamino acid pathway at baseline. High baseline levels of Firmicutes and low proportions of Bosea and Tetrasphaera were associated with response to antidepressant treatment. Based on inferred baseline metagenomic profiles, bacterial pathways that were significantly associated with treatment response were related to xenobiotics, amino acids, and lipid and carbohydrate metabolism, including tryptophan and drug metabolism. Metabolomic analyses showed that plasma tryptophan levels are independently associated with response to antidepressant treatment.
Our study has some limitations, including a lack of information on blood microbiome origin and the lack of a validation cohort to confirm our results.
Patients with depression have a distinct blood microbiome and metabolomic signature that changes after treatment. Dysbiosis could be a new therapeutic target and prognostic tool for the treatment of patients who are experiencing a major depressive episode.</abstract><cop>Canada</cop><pub>CMA Joule Inc</pub><pmid>34008933</pmid><doi>10.1503/jpn.200159</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1813-5128</orcidid><orcidid>https://orcid.org/0000-0001-6577-9009</orcidid><orcidid>https://orcid.org/0000-0002-0506-6688</orcidid><orcidid>https://orcid.org/0000-0001-5096-5722</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1180-4882 |
| ispartof | Journal of psychiatry & neuroscience, 2021-05, Vol.46 (3), p.E358-E368 |
| issn | 1180-4882 1488-2434 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8327971 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Antidepressants Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Bacteria Bacteria - classification Bacteria - drug effects Blood Blood - drug effects Blood - microbiology Brain-Gut Axis - drug effects Carbohydrate metabolism Carbohydrate Metabolism - drug effects Case-Control Studies Depressive Disorder, Major - blood Depressive Disorder, Major - complications Depressive Disorder, Major - drug therapy Depressive Disorder, Major - microbiology Dosage and administration Drug metabolism Drug therapy Dysbacteriosis Dysbiosis - blood Dysbiosis - complications Dysbiosis - metabolism Dysbiosis - microbiology Female Gastrointestinal Microbiome - drug effects Health care Humans Life Sciences Lipid metabolism Lipid Metabolism - drug effects Liquid chromatography Major depressive disorder Male Mass spectroscopy Mental depression Metabolism Metabolites Metabolome - drug effects Metabolomics Metagenomics Microbiomes Microbiota Microbiota (Symbiotic organisms) Microbiota - drug effects Patient outcomes Patients Permeability Physiological aspects Psychosis Psychotropic drugs Research Paper rRNA 16S Standard deviation Therapeutic targets Tryptophan Xenobiotics |
| title | Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20microbiota%20and%20metabolomic%20signature%20of%20major%20depression%20before%20and%20after%20antidepressant%20treatment:%20a%20prospective%20case-control%20study&rft.jtitle=Journal%20of%20psychiatry%20&%20neuroscience&rft.au=Ciocan,%20Dragos&rft.date=2021-05-01&rft.volume=46&rft.issue=3&rft.spage=E358&rft.epage=E368&rft.pages=E358-E368&rft.issn=1180-4882&rft.eissn=1488-2434&rft_id=info:doi/10.1503/jpn.200159&rft_dat=%3Cgale_pubme%3EA666502665%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564585986&rft_id=info:pmid/34008933&rft_galeid=A666502665&rfr_iscdi=true |